Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients.

Winther-Larsen, Anne; Fledelius, Joan; Demuth, Christina; Bylov, Catharina M; Meldgaard, Peter; Sorensen, Boe S

Winther-Larsen, Anne; Fledelius, Joan; Demuth, Christina; Bylov, Catharina M; Meldgaard, Peter; Sorensen, Boe S.

Afiliación

Winther-Larsen A; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. Electronic address: anlarsen@rm.dk.
Fledelius J; Department of Nuclear Medicine, Herning Regional Hospital, Herning, Denmark.
Demuth C; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Bylov CM; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
Meldgaard P; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Sorensen BS; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Transl Oncol ; 9(6): 505-511, 2016 Dec.

Article en En | MEDLINE | ID: mdl-27816687

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Transl Oncol Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google